Edwards Lifesciences has announced that the US District Court for the District of Columbia has approved an injunction motion issued by US Federal Trade Commission (FTC), putting the brakes on the medtech giant’s plans to acquire JenaValve. Edwards will no longer proceed with the acquisition of JenaValve, maker of a transcatheter aortic valve replacement system for aortic regurgitation (TAVR-AR). Disagreeing with the court’s decision, Edwards emphasised that the acquisition would have been in the best inte ...

Core Viewpoint - Edwards Lifesciences' proposed acquisition of JenaValve Technology has been blocked by a U.S. District Court ruling, which the company disagrees with, believing the acquisition would have benefited a significant patient population [1]. Group 1: Acquisition and Legal Matters - The U.S. Federal Trade Commission (FTC) successfully obtained an injunction to prevent Edwards Lifesciences from acquiring JenaValve Technology [1]. - Edwards Lifesciences asserts that the acquisition would have served the best interests of a large, growing, and underserved group of patients [1]. Group 2: Commitment to Aortic Regurgitation Therapy - Aortic regurgitation (AR) is identified as a serious and often under-detected disease with high mortality rates if untreated [2]. - Edwards Lifesciences is dedicated to leading AR therapy innovations, including the advancement of the SOJOURN transcatheter AR valve and the enrollment of patients in the JOURNEY pivotal trial [2]. Group 3: Financial Guidance Update - The company has revised its full-year 2026 adjusted earnings per share (EPS) guidance to a range of $2.90 to $3.05, up from the previous guidance of $2.80 to $2.95 [3].